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El Maı¨ et al. find that TRF2 is overex-
pressed in the vasculature of many can-
cer types. TRF2 is transcriptionally acti-
vated by the Wilms’ tumor suppressor
WT1 and contributes to angiogenesis by
activating transcription of the PDGFRb
gene.
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Telomeric repeat binding factor 2 (TRF2), which plays
a central role in telomere capping, is frequently
increased in human tumors. We reveal here that
TRF2 is expressed in the vasculature of most human
cancer types, where it colocalizes with the Wilms’
tumor suppressor WT1. We further show that TRF2
is a transcriptional target of WT1 and is required for
proliferation, migration, and tube formation of endo-
thelial cells. These angiogenic effects of TRF2 are
uncoupled from its function in telomere capping.
Instead, TRF2 binds and transactivates the promoter
of the angiogenic tyrosine kinase platelet-derived
growth factor receptor b (PDGFRb). These findings
reveal an unexpected role of TRF2 in neoangio-
genesis and delineate a distinct function of TRF2 as
a transcriptional regulator.INTRODUCTION
Telomeres are key features of linear chromosomes that preserve
genome stability and function. Variations in the telomere state
are critical for cell senescence, stem cell biology, and the devel-
opment of cancer (Hastie et al., 1990; Blackburn et al., 2006).
Human telomeres are composed of short, tandem repeated
TTAGGG DNA sequences and require the enzyme telomerase
to be fully replicated. The consequence of telomerase repres-
sion, which occurs at the end of embryogenesis in human so-
matic tissues, is that telomeric DNA shortens upon cell division
(Gilson and Ge´li, 2007; Hastie et al., 1990). This eventually leads
to critically short telomeres that initiate the DNA damage
response (DDR), thereby inducing senescence, apoptosis, and
tumor suppression (Deng et al., 2008). However, the DDR might
fail, leading to accumulation of telomere alterations and chro-
mosome rearrangements, which can contribute to cancer forma-
tion. Subsequent overexpression of telomerase is a key event in
tumor progression (Shay, 1997).
In addition to telomerase, telomere integrity relies on shelterin,
a DNA-bound protein complex composed of six different poly-Cell Rpeptides (TRF1, TRF2, RAP1, Tin2, TPP1, and Pot1; de Lange,
2005; Giraud Panis et al., 2013). The main telomere-capping
functions of this complex are to inhibit unwanted DDR activation
and repair at chromosome ends, prevent telomeric DNA degra-
dation, and regulate telomerase access and activity.
Some shelterin components, notably TRF2, are upregulated in
human cancer cells (Begemann et al., 2009; Biroccio et al., 2013;
Cookson and Laughton, 2009; Diala et al., 2013; Nakanishi et al.,
2003). Consistent with a potent oncogenic role of a high level of
TRF2, its downregulation in a variety of cancer cells reduces
tumorigenicity, whereas overexpression of TRF2 favors onco-
genesis (Begemann et al., 2009; Biroccio et al., 2006, 2013;
Blanco et al., 2007; Mun˜oz et al., 2005). Although a high level of
TRF2 expression in cancer cells is expected to maintain a suffi-
cient level of telomere functionality to prevent DDR activation
and chromosome instability and to sustain cell proliferation and
stemcell function, very little is known about its exact role in onco-
genesis. Recently, we showed that a high level of TRF2 in cancer
cells represses a nonautonomous cell pathway in which cancer
cells are eliminated by natural killer (NK) cells (Biroccio et al.,
2013). Strikingly, this function of TRF2 is not linked to its role in
telomere protection, but to its ability to bind at extratelomeric
sites and to modulate gene expression (Biroccio et al., 2013; Si-
monet et al., 2011; Yang et al., 2011; reviewed in Ye et al., 2014).
WT1 was originally identified as a tumor suppressor based on
its mutational inactivation in Wilms’ tumor or nephroblastoma
(Haber et al., 1990). However, due to its overexpression in
leukemia and a broad variety of solid human cancers, it is now
considered a potential oncogene (Hohenstein and Hastie,
2006). Moreover, mounting evidence indicates that WT1 plays a
key role in angiogenesis: it is highly expressed in thehuman tumor
vasculature and is required for endothelial cell migration, prolifer-
ation, and tube formation (Wagner et al., 2008). Furthermore, it is
implicated in vessel formation during embryonic development
(Wagner et al., 2005) and in pathophysiological conditions such
as myocardial infarction and ischemia (Wagner et al., 2002,
2003). In clinical trials of WT1 peptide vaccination, apart from
hematological malignancies, promising results in solid cancers
were obtained for glioblastomas and breast, lung, and renal car-
cinomas without systematic toxicity (Oka et al., 2008).
Here, we reveal that TRF2, like WT1, is frequently upregulated
in the endothelial cells of tumor vessels as compared with theeports 9, 1047–1060, November 6, 2014 ª2014 The Authors 1047
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Figure 1. TRF2 Is Expressed in Tumor Vessels of Different Human Cancers but Not in the Vasculature of Healthy Adjacent Tissues
(A) Representative examples of positive vascular immunostaining for TRF2 (3,30 diaminobenzidine [DAB] substrate, brown) of different human tumor types with
hematoxylin counterstaining.
(legend continued on next page)
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endothelial cells of healthy adjacent tissues. WT1 binds to and
transactivates the promoter of TRF2 in human umbilical vein
endothelial cells (HUVECs), which explains the expression of
TRF2 in tumor vessels. We further show that TRF2 stimulates
proliferation, migration, and tube formation in endothelial cells,
and knockdown of TRF2 impedes the angiogenic properties
of endothelium independently of its role in telomere capping.
Importantly, we uncover a mechanism by which TRF2 affects
angiogenesis: TRF2 binds and transactivates the promoter of
the angiogenic factor platelet-derived growth factor receptor b
(PDGFRb) (Battegay et al., 1994; Wyler von Ballmoos et al.,
2010), which has been reported to be expressed by tumor
endothelial cells (TECs) (Bhardwaj et al., 1996; Plate et al.,
1992). These findings delineate a function of TRF2 in neoangio-
genesis that is distinct from its role at telomeres, and may have
important implications for the use of TRF2 as a multiple target
in cancer therapy acting simultaneously on cancer cells and
tumor-associated endothelial cells.
RESULTS
TRF2 Is Upregulated in the Vessels of Various Tumors
We investigated 126 tumor samples of different cancer types for
vascular TRF2 expression. The samples included pancreas, co-
lon, prostate, breast, ovary, lung, and kidney cancers, as well
as glioblastoma, liposarcoma, and melanoma. Apart from its
frequent expression in cancer cells, we detected high vascular
TRF2 expression in 72% of the samples (Figure 1A; Table S1).
Confocal microscopy of tumor samples labeled for both TRF2
and PECAM-1 confirmed TRF2 localization in endothelial cells
(Figure 1B). This endothelial TRF2 expression was specific for
tumors, as no TRF2 expression could be detected in the vessels
of healthy adjacent tissues, independently of its expression in the
rest of the tissues (Figure 1C).
TRF2 Stimulates Migration, Proliferation, and Tube
Formation of Endothelial Cells
To determine the effects of TRF2 on angiogenesis, we trans-
duced HUVECs with an amphotropic virus encoding full-length
TRF2, a dominant-negative TRF2 form, or TERF2 small hairpin
RNA (shRNA), and the corresponding control vectors. Western
blot analysis confirmed TRF2 protein upregulation, the appear-
ance of a truncated TRF2 form, and downregulation of TRF2
protein (Figure 2A). Overexpression or knockdown of TRF2
respectively increased or decreased the migration of HUVECs
in scratch and Transwell migration assays, whereas the domi-
nant-negative form of TRF2 had no effect (Figures 2B–2D and
S1A). To investigate whether TRF2 alters the proliferation of
endothelial cells, we performed bromodeoxyuridine (BrdU)
incorporation assays and immunostaining for proliferating cell
nuclear antigen (PCNA), with subsequent quantification of
PCNA-positive cells relative to the total cell number. TRF2 over-
expression increased BrdU incorporation and the fraction of(B) Double labeling of TRF2 and PECAM-1. Nuclei were counterstained with DAP
(C) TRF2 expression in healthy tissues adjacent to different tumors. Note the lack
endothelial cells.
Scale bars indicate 50 mm. See also Table S1.
Cell RPCNA-positive cells significantly, knockdown of TRF2 had the
opposite effect, and dominant-negative TRF2 did not alter pro-
liferation compared with controls (Figures 2E, 2F, and S1B).
Cell-cycle analyses confirmed these findings in HUVECs (Fig-
ure 2G). No differences in the proliferative behavior of human
embryonic kidney 293 (HEK293) cells upon modulation of
TRF2 levels or expression of the dnTRF2 protein were observed,
despite effects on the telomere (Figure S1C), indicating the
specificity of the effects of TRF2 on proliferation of endothelial
cells (Figure S1D).
Next, we evaluated the consequences of modulated TRF2
levels on tubular network formation in Matrigel cultures. TRF2
knockdown impaired network formation of endothelial cells,
whereas TRF2 overexpression and dominant-negative TRF2
hadnoeffect (Figures2Hand2I). Todeterminewhether apoptosis
might contribute to the observed effects of TRF2 knockdown
on HUVEC functions, we used Annexin V/propidium iodide (PI)
labeling to detect early apoptotic events and TdT-dUTP terminal
nick-end labeling (TUNEL) to detect late apoptosis, followed by
fluorescence-activated cell sorting (FACS) analysis. Apoptosis
in HUVECs was not influenced by TRF2 overexpression, TRF2
knockdown, or dominant-negative TRF2 (Figures S1E–S1H).
The positive effects of Trf2 on migration, proliferation, and tube
formation of endothelial cells were confirmed in the murine
C166 endothelial cell line (Figures S2A–S2H).
TRF2 Is Implicated in the Enhanced Angiogenic
Properties of Tumor-Derived Endothelium
To investigate more specifically the relevance of the high TRF2
expression in TECs, we first performed a comparison of TRF2
levels in vascular cells derived from normal and cancer tissues.
Mouse primary endothelial cells were isolated either from normal
lungs (lung endothelial cells [LECs]) or tumors (TECs) induced by
subcutaneous LLC1 cancer cell injection. Purity was confirmed
by colabeling for Pecam-1 and VE-Cadherin, and subsequently
by FACS and confocal microscopy (Figures 3A–3D). In agree-
ment with the histological analysis of human cancer samples
(Figure 1), Trf2 expression was 3-fold upregulated in TECs
compared with LECs (Figure 3E). Next, we investigated the
effects of Trf2 overexpression on LECs (Figure 3F) and Trf2
knockdown (Figure 3H) on TECs. Trf2 overexpression increased
proliferation, migration, and tube formation of LECs (Figures 3G,
3K, and 3N), and Trf2 knockdown decreased these angiogenic
capabilities in TECS (Figures 3I, 3L, and 3O). Interestingly,
when the angiogenic properties of LECs and TECs were
compared without modulation of Trf2, TECs exhibited a higher
proliferation, migration, and tube formation capacity than LECs
(Figures 3J, 3M, and 3P), which further supports the angiogenic
function of TRF2.
TRF2 Is Positively Regulated byWT1 in Endothelial Cells
As the Wilms’ tumor suppressor WT1 is highly expressed in the
tumor vasculature and mediates angiogenesis in endothelialI.
of TRF2 expression in vessels of these tissues. Red arrows point to vessels and
eports 9, 1047–1060, November 6, 2014 ª2014 The Authors 1049
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Figure 2. TRF2 Is Involved in Endothelial Cell Migration, Proliferation, and Tube Formation of HUVECs
(A) Western blot confirming expression or knockdown of exogenous proteins in HUVECs.
(B) Representative photomicrographs of scratch migration assays under the conditions of different TRF2 levels or expression of the dnTRF2 protein (n = 6 each).
(C and D) Quantification of scratch (C) and Transwell (D) migration assays (n = 8 each).
(E and F) Quantification of BrdU incorporation assays (n = 8) (E) and the proportion of proliferating cell nuclear antigen (PCNA)-positive cells (F) as measures of
proliferation (n = 6).
(G) FACS-based cell-cycle analyses of HUVECs upon modulation of TRF2 (n = 4).
(H and I) Matrigel tube formation assays under the different conditions of TRF2 modulation and subsequent determination of branching points, tubule numbers,
and tubule lengths (n = 3).
Scale bars indicate 50 mm. Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figures S1 and S2.
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cells, we sought to determine whether TRF2 might be tran-
scriptionally regulated by WT1. Immunofluorescence double
labeling of human tumor samples revealed colocalization of
TRF2 and WT1 in tumor vessels of different cancer types (Fig-
ure S3A). To investigate whether endothelial Trf2 expression is
regulated by Wt1 in vivo, we used Wt1 conditional knockout
mice (Wt1lox/lox) (Martı´nez-Estrada et al., 2010) crossed with
a Tamoxifen-inducible VE-cadherin-Cre, which has been
described to be active in endothelial cells (Monvoisin et al.,
2006). In adult VE-CreERT2;Wt1lox/lox mice, Cre was activated
by Tamoxifen injection. VE-CreERT2;Wt1lox/lox injected with
vehicle served as a control (K.-D.W., J.-F.M.J., N.W., Cherfils,
N. Hosen, P. Hohenstein, E.G., and N.D. Hastie, unpublished
data). We analyzed the effects of endothelial Wt1 loss on
vascular Trf2 expression by knocking out Wt1 in VE-Cadherin+
cells through Tamoxifen injection, followed by subcutaneous
implantation of LLC1 lung carcinoma cells. Endothelial cells
were then isolated from the tumors by CD144 labeling and
subsequent FACS. Quantitative PCR (qPCR) analysis revealed
that upon loss of Wt1 in TECs, Trf2 levels were 3-fold
decreased (Figure 4A).
Next, we examined whether different WT1 expression levels in
human cells would result in similar changes in TRF2 expression.
Knockdown of WT1 in HUVECs led to a significant reduction
in TRF2 expression at the mRNA and protein levels (Figure 4B).
To upregulate WT1 expression, we made use of a stable osteo-
sarcoma-derived cell line (UB27 cells), which expresses the
WT1(–KTS) splice variant under the control of a tetracycline-sen-
sitive promoter (Englert et al., 1995). Removal of tetracycline
from the culture medium induced WT1 expression and caused
upregulation of TRF2 expression (Figure 4C). To determine
whether WT1 might also influence the expression of other
telomere factors, we induced WT1 expression in UB27 cells
and investigated the mRNA levels of TRF1, POT1, TIN2, RAP1,
TPP1, Apollo, and hTERT. We did not observe significant
changes in the expression of these telomere factors, apart
from a decrease in hTERT (Figure S3B) as previously described
(Sitaram et al., 2010).
To investigate whether WT1 can directly transactivate the
TRF2 promoter, we transiently cotransfected a luciferase
reporter construct containing nucleotides –1140 to +1 relative
to the transcription start site of the human TRF2 gene into
U2OS or HEK293 cells along with expression constructs
encoding two different WT1 protein forms. These two WT1 var-
iants differ by the presence/absence of three amino acids
(KTS) in the zinc finger domain of the molecule. Compared
with cotransfection of the empty expression vector, reporter
activity was stimulated >7-fold in U2OS cells and >5-fold
in HEK293 cells by the WT1(–KTS) expression construct. In
contrast, the WT1(+KTS) molecule, which has a role in mRNA
processing rather than in transcriptional regulation (Davies
et al., 1998), did not activate the TRF2 promoter. Deletion of
a predicted WT1 binding site in the TRF2 promoter (DWTB)
abolished transactivation of the TRF2 promoter upon cotrans-
fection with the WT1(–KTS) isoform (Figures 4D and 4E). Bind-
ing of WT1 to the TRF2 promoter in HUVECs was confirmed by
chromatin immunoprecipitation (ChIP) assays. The specificity
of the interaction of WT1 with the TRF2 promoter is indicatedCell Rby the lack of a PCR product when the same samples were
amplified with primers specific for the 30 UTR (Figures 4F
and 4G).
To determine whether TRF2 overexpression could rescue
the decreased migration and proliferation of HUVECs caused
by knockdown of WT1 (Wagner et al., 2008), we transduced
HUVECs with shWT1 and full-length TRF2 (Figures S3C and
S3D). TRF2 overexpression partially rescued the inhibition of
migration and proliferation caused by knockdown of WT1 (Fig-
ures 4H, 4I, and S3E), demonstrating that WT1 depends in part
on TRF2 for its proangiogenic functions.
TRF2Modulation in Endothelial Cells DoesNot Influence
Telomere Stability or the DDR
To evaluate whether the role of TRF2 in HUVEC functions is
linked to telomeres and the DDR, we scored telomere dysfunc-
tion-induced foci (TIFs), defined as foci of DDR factors that
coincide with telomeres, under the different TRF2 expression
conditions. The frequency of TIFs, as revealed by dual staining
for 53BP1 (a DDR protein) and TRF1 (used here as a telomere
marker), did not change in HUVECs expressing either the
dominant-negative form of TRF2 or a reduced amount of
TRF2 due to RNAi (Figures 5A–5C). Also in murine C166 cells
and ex vivo LECs and TECs, no changes in TIF frequencies
were observed upon TRF2 partial dysfunction (Figures S4A
and S4B). The expression of the same dominant-negative
TRF2 form and TRF2 shRNA as used with endothelial cells
increased the frequency of TIFs in HEK293 cells, ruling out a
technical problem in modulating and assaying TRF2 expres-
sion and activity (Figure S1C). In further agreement with the
absence of telomere deprotection in TRF2-compromised
HUVECs, no change in the activation of DDR factors, such as
phosphorylated H2AX, phosphorylated ATM, phosphorylated
p53, p21, and p16 in TRF2-compromised cells was observed
(Figures 5D and 5E).
Although we did not observe any change in ATM phosphoryla-
tion upon TRF2 modulation (Figure 5E), we investigated whether
the effects of TRF2 on HUVEC functions depend on ATM by
treating the cells with the ATM kinase-specific inhibitor KU-
55933 (Figures S5A and S5B). Blockade of ATM impairs the
growth and migration properties of HUVECs (Figures S5C–S5I),
ruling out the possibility that the angiogenic stimulation due to
TRF2 overexpression stems from ATM inhibition. The fact that
ATM inhibition impairs the proliferation of unperturbed cells
was previously reported (Li and Yang, 2010). Importantly, ATM
inhibition did not affect the increased migration and proliferation
due to TRF2 overexpression or the opposite effects observed
after reduction of TRF2 expression (Figures S5C–S5I).
Overall, we conclude that the effects of TRF2 on the angio-
genic properties of HUVECs do not correlate with changes
in telomere protection and DDR. Accordingly, they cannot be
explained merely by ATM modulation.
TRF2 Upregulates Expression of PDGFRb, and PDGFRb
Rescues the Effects of TRF2 Knockdown in Endothelial
Cells
Since the role of TRF2 in the angiogenic properties of endo-
thelial cells is not linked to telomere capping, we assessedeports 9, 1047–1060, November 6, 2014 ª2014 The Authors 1051
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Figure 3. Trf2 Mediates the Angiogenic Properties of Ex-Vivo-Derived Murine Endothelial Cells
(A and C) FACS analysis for VE-Cadherin and Pecam-1 expression of isolated endothelial cells from lungs (A) and tumors (C) of C57/BL6 animals.
(B and D) Confocal images of Pecam-1 (green) and VE-Cadherin (red) double-stained endothelial cells derived from lung (B) or tumor (D). Nuclei were stained
with DAPI.
(E) qRT-PCR analyses for Trf2 expression of lung- and tumor-derived endothelial cells (n = 3).
(F and H) qRT-PCRs for Trf2 expression upon (F) overexpression in LECs and (H) knockdown in TECs (n = 3 each).
(G, I, and J) Quantification of BrdU incorporation assays upon (G) overexpression of Trf2 in LECs and (I) knockdown in TECs, and (J) in LECs and TECs without
experimental modulation of Trf2 (n = 6 each).
(K and L) Quantification and representative images of scratch migration assays from (K) LECs overexpressing Trf2 and (L) TECs with knockdown of Trf2
(n = 3 each).
(legend continued on next page)
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whether TRF2 could regulate the expression of genes involved
in angiogenesis. For this purpose, we used a TaqMan Gene
Signature angiogenesis array to compare full-length TRF2-
and empty vector-transduced HUVECs (Figure S6). Five genes
were upregulated in HUVECs upon TRF2 overexpression:
Angptl1, Cxcl10, Figf, IFNB1, and PDGFRb. In this work, we
focused on PDGFRb. First, we confirmed that TRF2 overex-
pression increases PDGFRb expression at both the mRNA
and protein levels, and that TRF2 knockdown decreases its
expression (Figures 6A and 6B). In addition, increased AKT
phosphorylation indicated that TRF2 also upregulates a proper
PDGFRb target (Figure 6B). Confocal microscopy of endothelial
cells labeled for both TRF2 and PDGFRb confirmed higher
expression of PDGFRb in HUVECs, with overexpression of
TRF2 and reduced PDGFRb expression in cells with knock-
down of TRF2 (Figure 6C). WT1 induction in UB27 cells
increased PDGFRb expression (Figure S7A), and WT1(–KTS)
overexpression increased the activity of a PDGFRb promoter
construct, a response that was abolished by knockdown of
TRF2, indicating that WT1 indirectly activates PDGFRb through
its regulation of TRF2 (Figure S7B). In support of a role of
PDGFRb expression regulation by TRF2 in tumor vessels, we
observed colocalization of TRF2 and PDGFRb in tumor vessels
of different cancer types (Figure 6D).
As we observed that treatment of HUVECs with KU-55933
inhibited their migration and proliferation, which was abolished
by overexpression of TRF2, we investigated whether ATM
inhibition with KU-55933 might result in a downregulation
of PDGFRb expression. Indeed, treatment of HUVECs with
KU-55933 led to a significant decrease of PDGFRb expression
(Figure 6E). Interestingly, the effect of KU-55933 on PDGFRb
expression was not observed when TRF2 was overex-
pressed, further strengthening the notion that TRF2 regulates
HUVEC properties by positively controlling PDGFRb expression
(Figure 6E).
Next, we corroborated the importance of PDGFRb activation
for the function of TRF2 in the migration and proliferation of
endothelial cells by showing that the effects of TRF2 knockdown
are rescued through PDGFRb overexpression. Indeed, PDGFRb
overexpression not only reversed the inhibition of endothelial
cell migration and proliferation caused by knockdown of TRF2
but also had a stimulatory effect on both processes (Figures
6F–6H).
TRF2 Binds and Activates the PDGFRb Promoter
To determine whether TRF2 might directly activate the PDGFRb
promoter, we performed ChIP assays to analyze in HUVECs the
in vivo binding of TRF2 to various portions of the PDGFRb pro-
moter. Indeed, TRF2 binds to a 120-bp-long sequence within
the PDGFRb promoter region (T site), but not to the adjacent
sequence containing a G-rich sequence that is able to fold into
a G quadruplex (G site) or to the PDGFRb 30 UTR sequence (Fig-(M) Quantification of scratch migration assays from control LECs and TECs (n =
(N–P) Matrigel tube formation assays from (N) LECs overexpressing Trf2, (O) TE
determination of branching points, tubule numbers, and tubule lengths (n = 3 ea
Scale bars indicate 50 mm. Data are the mean ± SEM. *p < 0.05, **p < 0.01, ***p
Cell Rures 7A–7C). Although the T-site sequence does not contain a
stretch of TTAGGG sequences, it is bound by purified TRF2 in
electrophoretic mobility shift assays (EMSAs), albeit less effi-
ciently than a bona fide telomeric probe (Figure 7D). A deletion
of the single TTAGGG sequence present in the T site reduces
its recognition by TRF2 (Figure 7D), indicating that the binding
of TRF2 to the T site exhibits sequence specificity. In agreement
with the fact that the T site corresponds to a weak interstitial
TRF2 binding site, its occupancy is increased upon TRF2 over-
expression and decreased upon TRF2 depletion as revealed
by ChIP (Figure 7E).
To investigate whether TRF2 activates the PDGFRb promoter,
we performed transient transfection experiments in U2OS and
HEK293 cells, as the transfection efficiencies in HUVECs were
too low to give reproducible results. A luciferase reporter
construct containing the nucleotides between 1,750 and +
382 relative to the transcription start site of the human PDGFRb
gene, including the TRF2 binding region identified by ChIP and
EMSA, was cotransfected with the TRF2 expression construct.
TRF2 stimulated reporter activity >7-fold in both cell lines (Fig-
ure 7F). The dominant-negative form of TRF2 did not alter
PDGFRb promoter activity (Figure 7F). Transient transfection
with TRF2 expression constructs increased binding to the
cotransfected PDGFRb promoter plasmid (Figure 7G).
In transient transfection experiments, we confirmed that acti-
vation of the PDGFRb promoter was abolished with deletion of
the T site, whereas deletion of the G site did not affect activation
of the PDGFRb promoter by TRF2 (Figure 7H).
As prediction analyses revealed potential binding sites for
GATA2, ETS1, and ELK1 in close proximity to the sites of TRF2
binding in the PDGFRb promoter, we determined whether these
genesmight be necessary cofactors in the transcriptional activa-
tion of the PDGFRb promoter by TRF2. For this purpose, we
repeated the previous cotransfection experiments in the pres-
ence of siRNAs against GATA2, ETS1, and ELK1, respectively.
Knockdown of these genes did not affect the transactivation of
PDGFRb by TRF2 (Figure S7C).
DISCUSSION
Angiogenesis is important for cancer progression. Here, we
unveil that TRF2 is frequently upregulated in endothelial cells
of tumor vessels as compared with those of the vasculature of
normal tissues, suggesting a role of TRF2 in neoangiogenesis
(Figures 1 and 3). This upregulation of TRF2 in tumor vessel cells
likely results from the fact that the TRF2 promoter is a target of
WT1, which is highly expressed in the human tumor vasculature
(Wagner et al., 2008) and directly transactivates the TRF2 pro-
moter (Figure 4). Therefore, TRF2 expression might be regulated
by WT1 in vessel development and pathologies.
Our gain- and loss-of-function studies of TRF2 in human
and murine endothelial cells demonstrate that TRF2 positively3 each).
Cs knocked down for Trf2, and (P) control LECs and TECs, and subsequent
ch).
< 0.001.
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regulates migration, proliferation, and tube formation. These re-
sults are in agreement with a previous study implicating TRF2 in
the migratory behavior of endothelial progenitor cells (Spyrido-
poulos et al., 2004). We did not observe telomere dysfunction
or the DDR upon TRF2 modulation in HUVECs, making it un-
likely that TRF2 impacts the angiogenic properties of HUVECs
through its role in telomere capping. In further accord with the
notion that the role of TRF2 in angiogenesis is uncoupled from
its telomere-capping function, the expression of a dominant-
negative form of TRF2 that lacks the N-terminal basic domain
and C-terminal telobox domain (van Steensel et al., 1998),
and is known to uncap telomeres, does not impair the migration,
proliferation, and tube formation capacity of endothelial cells, as
it occurs with a reduced expression of TRF2. Nevertheless,
because expression of the dominant-negative form neither en-
hances HUVEC proliferation and migration nor activates the
PDGFRb promoter, in contrast to the wild-type full-length pro-
tein, the N- and/or C-terminal part of TRF2 might be required
for its proangiogenic effects. Finally, since ATM is a direct target
of TRF2 upon DNA damage (Karlseder et al., 2004), we tested
whether ATM is involved in the angiogenic properties of TRF2.
Inhibition of ATM activity does not change either the proangio-
genic functions of TRF2 overexpression or the antiangiogenic
properties of TRF2 downregulation, ruling out the possibility
that the effects of TRF2 on angiogenesis are mediated by
ATM modulation.
Strikingly, the modulations of the angiogenic properties of
endothelial cells triggered by TRF2 up- or downregulation are
not accompanied by an overt telomere deprotection and are in-
dependent of ATM. Previous studies involving various types of
cancer cells suggested that a reduced expression of TRF2might
not be enough to trigger DDR activation at telomeres (Takai et al.,
2010; Cesare et al., 2013; Biroccio et al., 2013). Moreover,
the uncoupling of TRF2’s function in telomere protection and
the ability of cancer cells to escape immunosurveillance was
previously attributed to an extratelomeric role of TRF2 in gene
expression (Biroccio et al., 2013). Our results show that a relatedFigure 4. Vascular-Specific Knockout of Wt1 Decreases Endothelial
Promoter, and TRF2 Overexpression Partially Rescues the Effects of W
(A) qRT-PCRs for the expression of Wt1 and Trf2 in endothelial cells, is
VE-CreERT2;Wt1lox/lox mice (vehicle or Tamoxifen treated; n = 3). Note the signifi
(B) qRT-PCRs and representative western blots for WT1 and TRF2 upon knockd
(C) qRT-PCRs and representative western blots for WT1 and TRF2 upon inductio
(D) Transient transfection in U2OS and HEK293 cells. The TRF2 promoter in a lucif
the WT1 binding site (DWTB) were transiently cotransfected together with W
normalized to the activity of cotransfected b-galactosidase (n = 8).
(E) Schematic representation of the putative WT1 binding site in the TRF2 promo
positions, and sequences of the putative WT1 binding site, and positions of the ol
construct, the indicated WT1 binding site was removed from the promoter repor
(F) qRT-PCRs of ChIP assay-derived samples (n = 3) demonstrating binding of W
HUVECs. Input DNA (dilution 1:5 and 1:10) and immunoprecipitates obtainedwith
rabbit serum was used instead of the specific antibody as a negative control.
(G) PCR-amplified products from the immunoprecipitates electrophoresed on a
(H) Scratch migration assays for TRF2-mediated rescue of WT1 knockdown. Not
with knockdown of WT1, but fails to restore the migration capacity to control lev
(I) BrdU incorporation assays for TRF2 overexpression and knockdown of WT1, s
knockdown of WT1 (n = 8).
Scale bars indicate 50 mm. Data are the mean ± SEM. *p < 0.05, **p < 0.01, ***p <
shRNA alone. See also Figure S3.
Cell Runcoupling between telomere protection and angiogenesis can
also occur in primary endothelial cells thanks to TRF2’s role in
activating the PDGFRb promoter (Figure 7).
PDGFRb promotes early endothelial cell differentiation (Rolny
et al., 2006) and was recently shown to stimulate migration, pro-
liferation, and tube formation of differentiated endothelial cells
(Wyler von Ballmoos et al., 2010). PDGFRb overexpression
rescued the inhibition of proliferation caused by knockdown of
TRF2, but only partially relieved the inhibition of migration. This
suggests that in addition to PDGFRb, TRF2 might also activate
other factors involved in cellular migration. Like TRF2,WT1 upre-
gulated the expression of PDGFRb. Since reduced expression of
TRF2 abolished PDGFRb activation by WT1, TRF2 seems to be
required for WT1-dependent PDGFRb activation. Therefore, we
propose that during neoangiogenesis, WT1 upregulates TRF2
expression, which in turn increases the expression of the angio-
genic factor PDGFRb.
The idea that TRF2 regulates gene expression independently
of its roles in telomere capping is not unprecedented (reviewed
in Ye et al., 2014). For example, TRF2 plays a role in neuronal
differentiation by binding to the neuronal gene repressor
RE1-silencing transcription factor (REST) (Zhang et al., 2008,
2011). Moreover, TRF2 also binds to extratelomeric DNA
sequences (Simonet et al., 2011; Yang et al., 2011), where it
can act as a regulator of gene expression (Biroccio et al.,
2013). However, the extratelomeric mechanisms by which
TRF2 regulates gene expression are still unclear. Thus, the
observation that TRF2 directly transactivates the PDGFRb pro-
moter is likely to reveal new properties of TRF2 and possibly of
its protein partner RAP1, which is also involved in regulating
gene expression outside of telomeres (Martinez et al., 2010,
2013; Yeung et al., 2013). Interestingly, within the PDGFRb pro-
moter region, TRF2 binds weakly, but in a sequence-specific
manner, to a 120 bp fragment that is required for TRF2-depen-
dent promoter transactivation and contains a single TTAGGG
sequence involved in TRF2 binding. Thus, we conclude that
the PDGFRb promoter contains a TRF2 binding site that isTrf2 Expression In Vivo, WT1 Binds and Transactivates the TRF2
T1 Knockdown on Endothelial Cell Migration and Proliferation
olated by VE-Cadherin labeling and subsequent FACS from tumors of
cant reduction of endothelial Trf2 expression upon knockout of Wt1.
own of WT1 in HUVECs (n = 3).
n of WT1 in UB27 cells (n = 6).
erase reporter plasmid (pGL3basic) and the promoter construct with deletion of
T1(–KTS) and WT1(+KTS) expression constructs. Luciferase activities were
ter. The positions of the cloned promoter relative to the transcription start site,
igonucleotides used for ChIP analyses are indicated. For the promoter deletion
ter construct.
T1 protein to the TRF2 promoter, but not to the 30 UTR of the TRF2 gene, in
an acetylated histone 3 antibody (acetyl H3) served as positive controls. Normal
2% agarose gel and stained with ethidium bromide.
e that overexpression of TRF2 significantly enhances the migration of HUVECs
els (n = 3).
howing partial rescue of proliferation by TRF2 overexpression in HUVECs with
0.001, ###p < 0.001 comparing the condition WT1 shRNA + TRF2 versus WT1
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Figure 5. TRF2Modulation in HUVECs Does
Not Alter TIFs or DDRs
(A) Representative confocal images of detection of
colocalization of TRF1 (green) and 53BP1 (red) at
TIFs under the indicated conditions (n = 4).
(B) Quantification of the number of 53BP1 big
spots per nucleus.
(C) Quantification of the number of TIFs per
nucleus.
(D) Western blot analysis of the expression of DDR
(y-H2AX) and senescence (phospho-p53, p21, and
p16) markers under the indicated conditions.
(E) Western blot for phospho-ATM under the
different conditions.
Scale bars indicate 10 mm. Data are the mean ±
SEM. ***p < 0.001. See also Figures S4 and S5.partially occupied in HUVECs and exhibits TRF2-dependent
transactivation properties.
Collectively, these findings reveal that besides its roles
in tumor cells related to telomere capping and immunosur-
veillance, TRF2 functions in endothelial cells to regulate the1056 Cell Reports 9, 1047–1060, November 6, 2014 ª2014 The Authorsexpression of angiogenic factors. The
observation that telomere shortening
and DDR activation promote TRF2
degradation (Fujita et al., 2010) raises
the question as to whether these neoan-
giogenic properties of TRF2 can be
modulated by telomere changes in endo-
thelial cells.
This work suggests pharmacological
strategies for targeting the extratelo-
meric functions of TRF2 in TECs, in addi-
tion to cancer cells, without inducing
telomere deprotection and chromosome
instability. Thus, TRF2 emerges as a
potentially valuable multitarget for cancer
treatment.
EXPERIMENTAL PROCEDURES
This study adhered to the principles of the Decla-
ration of Helsinki and to Title 45 of the U.S. Code
of Federal Regulations (Part 46, Protection of
Human Subjects). In total, 126 paraffin-embedded
tumor samples (Table S1) were used for the
detection of TRF2.
All animals were used in accord with the French
Coordination Committee on Cancer Research
guidelines and local Home Office regulations.
VE-Cadherin-CreERT2 mice obtained from
L. Iruela-Arispe were crossed with Wt1lox/lox ani-
mals obtained from N.D. Hastie to generate the
VE-CreERT2;Wt1lox/lox strain.
HUVECs were grown in endothelial cell growth
medium. For all experiments, we used HUVECs
pooled from up to four donors and did not exceed
passage 4. HEK293 cells and U2OS osteosar-
coma cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM). U2OS osteosarcoma
cells (clone UB27) with tetracycline-repressibleexpression of Wt1(KTS) were a gift from Dr. C. Englert. LLC1 mouse lung
cancer cells were grown in DMEM-F12 medium, and C166 mouse endothelial
cells were grown in DMEM. Mouse LECs and TECs were isolated from C57/
BL6 mice. Endothelial cells were purified from the cell suspensions using a
rat anti-CD31 antibody conjugated to Dynabeads and a magnetic particle
concentrator, and cultured in DMEM. Endothelial cell purity was confirmed
A B C
D E
F G H
Figure 6. TRF2 Upregulates Expression of PDGFRb, and PDGFRb Rescues the Effects of TRF2 Knockdown in Endothelial Cells
(A) qRT-PCRs for PDGFRb upon overexpression and knockdown of TRF2 in HUVECs (n = 4).
(B) Western blots for TRF2, PDGFRb, pAKT, and AKT. b-tubulin served as standard.
(C) Confocal images of PDGFRb (green) and TRF2 (red) double-stained HUVECs transduced with full-length TRF2 or TERF2 shRNA. Nuclei were stained
with DAPI.
(D) Double labeling of TRF2 and PDGFRb in human tumor samples. Nuclei were counterstained with DAPI. Yellow arrows point specifically to some of the
colabeled endothelial cells.
(E) qRT-PCRs for PDGFRb upon treatment with KU-55339 and TRF2 overexpression in HUVECs (n = 4).
(F) qRT-PCRs for TRF2 and PDGFRb expression upon knockdown of TRF2 and overexpression of PDGFRb (n = 3).
(G and H) Quantification of (G) scratch (n = 3) migration assays and (H) BrdU incorporation assays (n = 6) for PDGFRb overexpression, TERF2 shRNA, and
combined TERF2 shRNA + PDGFRb overexpression.
Scale bars indicate 10 mM in (C) and 50 mm in (D). Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ###p < 0.001 comparing the condition PDGFRb +
TERF2 shRNA versus TERF2 shRNA. See also Figures S6 and S7.by FACS analysis. On HUVECs, mouse C166 endothelial cells and primary
mouse endothelial cells isolated from lungs and tumors, we performed scratch
migration, BrdU proliferation, and in vitro tube formation assays and investi-
gated the frequency of TIFs under conditions of TRF2 overexpression or
knockdown.
More specific details regarding the experimental procedures used for
immunohistology, cell culture, transduction, assays (migration, proliferation,
tube formation, and apoptosis), immunofluorescence, qRT-PCR, SDS-
PAGE, western blotting, cloning strategies and transfections, EMSAs, and
ChIP assays are given in the Supplemental Experimental Procedures. Data
are expressed as means ± SEM. ANOVA with the Bonferroni test as a post
hoc test or Mann-Whitney tests were performed as indicated. A p value <
0.05 was considered statistically significant.Cell RSUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.09.038.
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